Program
Deuruxolitinib
Also written as “CTP-543”, “[14C]-CTP-543” and “CTP-543, 16 mg (2 x 8 mg tablet)”.
Its studies are mostly in Alopecia Areata · Renal Insufficiency, led by Sun Pharmaceutical Industries.
Drug pageDeuruxolitinib: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | 233 open or running | phase 3since Mar 29, 2019 | May 16, 2016 | May 2027phase 3 · NCT03898479 |
Also a collaborator on its studies: Celerion.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 6 studies since May 16, 2016.
- May 6, 2019Phase 2 study in Alopecia AreataNCT03941548 · 66 enrolled · United States, Canada
- Sep 5, 2019Phase 1 study in Healthy VolunteersNCT04092712 · 6 enrolled · United States
- Mar 11, 2020Phase 1 study in Healthy VolunteersNCT04309643 · 21 enrolled · United States
- Aug 16, 2020Phase 3 study in Alopecia AreataNCT04518995 · 706 enrolled · United States, Canada, France and more
- Dec 19, 2020Named deuruxolitinibINNProposed as its International Nonproprietary Name in WHO's List 124 · before, CTP-543
- Feb 4, 2021Phase 1 study in Healthy VolunteersNCT04743414 · 22 enrolled · United States
- Mar 3, 2021Phase 2 study in Alopecia AreataNCT04784533 · 317 enrolled · United States
- Mar 10, 2021Phase 3 study in Alopecia AreataNCT04797650 · 517 enrolled · United States, Canada, France and more
- Apr 9, 2021Phase 1 study in Healthy VolunteersNCT04843540 · 22 enrolled · United States
- Sep 3, 2021Phase 3 study in Alopecia AreataNCT05041803 · 407 enrolled · France, Germany, Hungary and more
- Jan 5, 2022Phase 1 study in Healthy VolunteersNCT05192369 · 48 enrolled · United States
- Jun 30, 20224 phase 1 studiesNCT05468749, NCT05467722, NCT05467709 and 1 more
- Jul 26, 2022Phase 1 study in Health VolunteersNCT05478772 · 18 enrolled · United States
- Jul 29, 2025Phase 3 study in Alopecia AreataNCT07133308 · 355 planned · United States, Canada
- May 22, 2026Phase 3 study in Alopecia AreataNCT07617597 · 78 planned · Japan
Ahead
- May 2027Primary completion: phase 3 study in Alopecia AreataNCT03898479
- Feb 2028Primary completion: phase 3 study in Alopecia AreataNCT07617597
- May 2028Primary completion: phase 3 study in Alopecia AreataNCT07133308
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07617597Alopecia Areata · Japan | 3 | Recruiting | Feb 2028 | 78 |
| NCT07133308Alopecia Areata · United States, Canada | 3 | Recruiting | May 2028 | 355 |
| NCT05478772Health Volunteers · United States | 1 | Completed | Aug 6, 2022 | 18 |
| NCT05468749Renal Insufficiency · United States | 1 | Completed | Oct 20, 2022 | 16 |
| NCT05467722Hepatic Impairment · United States | 1 | Completed | Sep 15, 2022 | 21 |
| NCT05467709Health Volunteers · United States | 1 | Completed | Jun 30, 2022 | 20 |
| NCT05467696Health Volunteers · United States | 1 | Completed | Jun 26, 2022 | 16 |
| NCT05192369Healthy Volunteers · United States | 1 | Completed | Jan 28, 2022 | 48 |
| NCT05041803Alopecia Areata · France, Germany, Hungary and more | 3 | Completed | Jul 18, 2024 | 407 |
| NCT04843540Healthy Volunteers · United States | 1 | Completed | Jun 24, 2021 | 22 |
| NCT04797650Alopecia Areata · United States, Canada, France and more | 3 | Completed | Jun 8, 2022 | 517 |
| NCT04784533Alopecia Areata · United States | 2 | Completed | May 16, 2023 | 317 |
| NCT04743414Healthy Volunteers · United States | 1 | Completed | Mar 27, 2021 | 22 |
| NCT04518995Alopecia Areata · United States, Canada, France and more | 3 | Completed | Apr 19, 2022 | 706 |
| NCT04309643Healthy Volunteers · United States | 1 | Completed | Jun 25, 2020 | 21 |
| NCT04092712Healthy Volunteers · United States | 1 | Completed | Sep 11, 2019 | 6 |
| NCT03941548Alopecia Areata · United States, Canada | 2 | Completed | Apr 10, 2020 | 66 |
| NCT03898479Alopecia Areata · United States, Canada | 3 | Active, not recruiting | May 2027 | 1,000 |
| NCT03880136Healthy · United States | 1 | Completed | Apr 5, 2019 | 14 |
| NCT03811912Alopecia Areata · United States | 2 | Completed | Nov 21, 2019 | 57 |
| NCT03137381Alopecia Areata · United States | 2 | Completed | Jul 8, 2019 | 149 |
| NCT02960945Healthy · United States | 1 | Completed | Jan 2017 | 12 |
| NCT02777008Healthy · Australia | 1 | Completed | Dec 2016 | 77 |
How it is read
Names in the registry
- “CTP-543”, 21 entries
- “Deuruxolitinib”, 2 entries
- “[14C]-CTP-543”, 1 entry
- “CTP-543, 16 mg (2 x 8 mg tablet)”, 1 entry
Conditions, from the studies’ own filings
- Alopecia Areata, 10 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.